がん治療用キナーゼ阻害剤の世界市場

◆英語タイトル:Kinase Inhibitors for Cancer Treatment: World Industry Analysis, R&D and Market Forecasts 2015-2025
: Explore the Potentials of New Drugs

◆商品コード:VGAIN5081916
◆発行会社(リサーチ会社):visiongain
◆発行日:2015年8月
◆ページ数:221
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Sigle UserGBP1,799 ⇒換算¥268,051見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥446,851見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥744,851見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、がん治療用キナーゼ阻害剤の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・がん治療用キナーゼ阻害剤の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・主要ながん治療用キナーゼ阻害剤
・地域別市場分析、市場規模予測
・がん治療用キナーゼ阻害剤研究開発パイプライン
・市場環境分析
・専門家の見解
・主要企業分析
・結論
【レポートの概要】

Kinase Inhibitors – Benefit Your Influence Now by Discovering Their Sales Potentials
Do you want to find sales potentials of protein kinase inhibitors for treating cancer? You can now explore the latest research and development and market predictions. Our new study shows you R&D trends, results, opportunities and multilevel revenue forecasts.

Visiongain’s report shows you what is possible for drugs using protein kinase inhibition. That way you assess the future of cancer treatment. Find progress in that rising industry and market, discovering expected progress and sales, including the influence of new products.

Avoid missing out. With our research and analysis you assess trends, companies and products, benefiting your reputation for technological and commercial insight. That way discover what is possible from 2015.

Progress of that industry – discover prospects for those novel anti-cancer medicines
Are you tired of struggles to find business data on cancer therapy? Instead benefit your work through our new study, seeing how to help your data searches, analyses, decisions, proposals and presentations.

With our new study you explore the future of those therapies. Read on, then, to investigate that industry and see how high its future sales could go.

Forecasts and other information showing technical, clinical and commercial possibilities
The new study gives you sales predictions to 2025 at overall world market, submarket, company, product and national level. See what the future holds for those advances in cancer therapy. For kinase-inhibiting drugs you investigate where demand and money lie.

In our work you receive 83 tables, 73 charts and two interviews with other authorities. Besides giving revenue predictions, our new analysis shows recent results, growth rates and market shares.

Although no single study covers everything, the following sections show how our new investigation benefits your work.

Forecasting of that world market and its segments – what’s possible for those treatments?
What is the potential of that biomedical industry? What are the secrets of its progress? Discover in our report overall world revenue to 2025 for inhibition of protein kinases.

There you also find individual revenue predictions to 2025 for eight submarkets at world level:
• Bcr-Abl tyrosine-kinase inhibitors (TKI)
• Angiogenesis inhibitors
• EGFR inhibitors
• mTOR inhibitors
• BRAF and MEK inhibitors
• Other kinase inhibitors
• Pipeline drugs
• Generics and other agents.

Our work investigates products, uses and revenues past and future. That way you assess outlooks for expansion in trade, seeing where potential sales increases can appear, helping you stay ahead.

The new study also explores competition. There you investigate activities of developers, producers and marketers of kinase inhibiting medicines, understanding their challenges, trends and outlooks. You also examine revenues by product.

Product forecasts – investigate sales potentials of existing and expected therapies
How will top marketed and expected kinase treatments perform to 2025 at world level?

Our new analysis shows you individual revenue predictions for 28 marketed products, including these drugs:
• Glivec (imatinib)
• Sprycel (dasatinib)
• Tasigna (nilotinib)
• Tarceva (erlotinib)
• Nexavar (sorafenib)
• Sutent (sunitinib)
• Afinitor (everolimus)
• Imbruvica (ibrutinib).

That study includes profiles for 23 medicines in development and revenue forecasts for seven leading drug candidates, including these agents:
• Venetoclax (ABT-199)
• Duvelisib (IPI-145)
• Buparlisib (BKM120)
• Cobimetinib (GDC-0973).

With our analysis you discover sales potentials for leading brands of those enzyme inhibitors. Discover what is possible, from 2015, for transforming that industry and market.

Also our survey splits its overall world market into geographical revenue predictions.

National markets for those drug sales – what does the future hold?
Advances in biotechnology and healthcare expand use of anti-cancer drugs, including protein kinase inhibitors. Our study shows you prospects for those sales in developed and developing regions.

There see individual revenue forecasting to 2025 for 11 countries:
• United States (US)
• Japan
• Germany, France, United Kingdom (UK), Italy and Spain, also with overall EU prediction
• Brazil, Russia, India and China (BRIC nations).

With our analysis you investigate countries with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.

Also how do events, challenges and advances in technology affect that industry and market? Our report shows you, discussing progress, policies and trends.

Forces affecting developers, producers and sellers of those pharmaceuticals
Our study explains issues, events and R&D affecting that oncology from 2015, including these advances:
• Cyclin-dependent kinase 4/6 and ALK inhibitors in development
• Bruton’s tyrosine kinase and PI3K agents for the future
• MEK and BRAF inhibition – prospects for new treatments.

Also explore these trends and influences, among others, assessing their impact:
• Stratification of patients and cancer genomics for more-personalised medicine
• Ageing populations and rising cancer prevalence increasing demand
• Generic competition – challenges for original branded drugs
• Biologics – including monoclonal antibodies (mAbs)
• Combination therapies – potential for improvements in treating patients.

Our study explains that industry’s strengths, weaknesses, opportunities and threats. It also explores social, technological, economic and political questions. Those methods let you analyse that market, its progress and potential, discovering from 2015 what is possible.

Kinase inhibitors for treating cancer – what revenues are likely by 2019?
What happens next? From 2015, protein kinase inhibitors for treating cancer patients hold great potential for investments, technological advances and sales. Visiongain predicts the world market for those products will grow to $31.2bn in 2019, with further expansion to 2025.

In particular our study explores activities and potentials of nine companies, forecasting revenues to 2025 for seven firms:
• Novartis
• Pfizer
• Roche
• Bristol-Myers Squibb
• Bayer
• AstraZeneca
• Gilead Sciences.

Our survey also shows interviews by visiongain with other authorities on anti-cancer kinase inhibitors:
• Infinity Pharmaceuticals
• LYMMCARE (Lymphoma and Myeloma Center Amsterdam).

【レポートの目次】

1. Report Overview
1.1 Overview of the Protein Kinase Inhibitor Market for Cancer Treatments, 2015
1.2 Benefits of This Report
1.2.1 How This Report Delivers
1.2.2 Main Questions Answered by this Analytical Study
1.3 Who is This Report For?
1.4 Methods of the Study
1.5 Frequently Asked Questions (FAQ)
1.6 Associated Visiongain Reports
1.7 About Visiongain

2. Introduction to Anti-Cancer Kinase Inhibitors
2.1 What are Protein Kinases and Protein Kinase Inhibitors?
2.2 Protein Kinases in Oncology
2.3 Glossary

3. Leading Anti-Cancer Kinase Inhibitor Drugs: Forecasts and Discussions, 2015-2025
3.1 Brc-Abl Inhibitors – Transforming Chronic Myeloid Leukaemia from a Fatal Diagnosis To a Managed Lifestyle
3.1.1 Glivec/Gleevec (imatinib) – Novartis
3.1.2 Sprycel (dasatinib) – Bristol-Myers Squibb
3.1.3 Tasigna (nilotinib) – Novartis
3.1.4 Bosulif (bosutinib) – Pfizer
3.1.5 Iclusig (ponatinib) – ARIAD Pharmaceuticals
3.2 EGFR Inhibitors Target a Mutation-Positive Market
3.2.1 Tarceva (erlotinib) – Roche/Astellas
3.2.2 Iressa (gefinitib) – AstraZeneca
3.2.3 Gilotrif/Giotrif (afatinib) – Boehringer Ingelheim
3.3 Angiogenesis Inhibitors Have a Variety of Indications
3.3.1 Nexavar (sorafenib) – Bayer/Onyx
3.3.2 Sutent (sunitinib) – Pfizer
3.3.3 Votrient (pazopanib) – Novartis
3.3.4 Inlyta (axitinib) – Pfizer
3.4 BRAF and MEK Inhibitors: A Promising Combination
3.4.1 Zelboraf (vemurafenib) – Roche
3.4.2 Mekinist (trametinib) and Tafinlar (dabrafenib) – Novartis
3.5 mTOR Inhibitors Have a New Entrant
3.5.1 Afinitor/Votubia (everolimus) – Novartis
3.5.2 Torisel (temsirolimus) – Pfizer
3.5.3 Zydelig (idelalisib) – Gilead Sciences
3.6 Other Leading Cancer Inhibitors Are a Varied Group
3.6.1 Imbruvica (ibrutinib) – J&J/Pharmacyclics/AbbVie
3.6.2 Jakavi/Jakafi (ruxolitinib) – Novartis/Incyte
3.6.3 Xalkori (crizotinib) – Pfizer
3.6.4 Cometriq (cabozantinib) – Exelixis
3.6.5 Caprelsa (vandetanib) – AstraZeneca
3.6.6 Tyverb/Tykerb (lapatinib) – Novartis
3.6.7 Stivarga (regorafenib) – Bayer
3.6.8 Zykadia (ceritinib, LDK378) – Novartis
3.6.9 Ibrance (palbociclib) – Pfizer
3.6.10 Alectinib (AF802) – Roche

4. Anti-Cancer Kinase Inhibitors: World Market Outlook and Forecast, 2015-2025
4.1 Global Anti-Cancer Kinase Inhibitors Market: Leading Kinase Inhibitors in 2014
4.2 World Anti-Cancer Kinase Inhibitors Market: Revenue Forecasts and Change in Market Shares by Class 2015-2025
4.3 Bcr-Abl Inhibitors Lead the Anti-Cancer Kinase Inhibitors Market in 2015
4.3.1 Drivers and Restraints of the Bcr-Abl Kinase Inhibitors Market 2015-2025
4.4 Novel Kinase Inhibitors Will Dominate the Market As They Cover a Broad Range
4.4.1 Drivers and Restraints of these Other Kinase Inhibitors 2015-2025

5. Leading National Markets for Anti-Cancer Kinase Inhibitors, 2015-2025
5.1 Regional Breakdown of the Global Anti-Cancer Kinase Inhibitors Market, 2014
5.2 World Anti-Cancer Kinase Inhibitors Market: Regional Forecast 2015-2025
5.3 How Will Regional Market Shares Change through to 2025?
5.4 The US Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025
5.4.1 Drivers and Restraints of the US Anti-Cancer Kinase Inhibitors Market 2015-2025
5.5 The EU Anti-Cancer Kinase Inhibitors Market 2015-2025
5.5.1 Drivers and Restraints of the EU Anti-Cancer Kinase Inhibitors Market 2015-2025
5.5.2 German Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025
5.5.3 French Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025
5.5.4 Italian Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025
5.5.5 UK Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025
5.5.6 Spanish Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025
5.6 Japanese Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025
5.7 The Anti-Cancer Kinase Inhibitors Emerging Market: BRIC 2015-2025
5.7.1 China: Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025
5.7.2 India: Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025
5.7.3 Brazil: Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025
5.7.4 Russia: Anti-Cancer Kinase Inhibitors Market Forecast 2015-2025

6. Anti-Cancer Kinase Inhibitors: R&D Pipeline, 2015
6.1 Cyclin-Dependent Kinase 4/6 Inhibitors in Development
6.1.1 LEE-011 – Novartis
6.1.2 Abemaciclib (LY2835219) – Eli Lilly
6.2 ALK Inhibitors in Development
6.2.1 Brigatinib (AP26113) – ARIAD Pharmaceuticals
6.3 Bruton’s Tyrosine Kinase and PI3K Inhibitors in Development
6.3.1 Venetoclax (ABT-199/RG7601/GDC-0199)– Roche/AbbVie
6.3.2 Duvelisib (IPI-145) – Infinity Pharmaceuticals/AbbVie
6.3.3 Buparlisib (BKM120) – Novartis
6.3.4 ONO-4059 – ONO Pharmaceutical/Gilead Sciences
6.3.5 Copanlisib (BAY 80-6946) – Bayer
6.3.6 Pictilisib (GDC-0941/RG7321) – Roche
6.3.7 BEZ235 – Novartis
6.4 MEK and BRAF Inhibitors in Development
6.4.1 Cobimetinib (GDC-0973/XL518) – Exelixis/Roche
6.4.2 Encorafenib (LGX818) & Binimetinib (MEK162)– Array BioPharma
6.4.3 Selumetinib (AZD 6244) – AstraZeneca/Array BioPharma
6.5 Other Anti-Cancer Kinase Inhibitors in Development
6.5.1 Volasertib – Boehringer Ingelheim
6.5.2 Neratinib (PB272) – Puma Biotechnology
6.5.3 Tivantinib (ARQ197) – Daiichi Sankyo/ArQule
6.5.4 Dovitinib (TKI258) – Novartis
6.5.5 Dacomitinib – Pfizer
6.5.6 Rociletinib (CO-1686) – Clovis Oncology
6.5.7 Entrectinib (RXDX-101) – Ignyta
6.5.8 INC280 and EGF816 – Novartis

7. Leading Companies in the Anti-Cancer Kinase Inhibitors Market, 2015
7.1 Leading Companies in the Anti-Cancer Kinase Inhibitors Market by Revenue, 2014
7.1.1 Leading Anti-Cancer Kinase Inhibitors Manufacturers: Revenue Forecasts, 2015-2025
7.2 Leading Anti-Cancer Kinase Inhibitor Company Profiles
7.2.1 Novartis: Interesting Developments and a Continued Lead on the Market
7.2.2 Pfizer: Advancing Closer to Novartis’ Lead
7.2.3 Roche: A Global Giant in Cancer Treatment
7.2.4 Bristol-Myers Squibb’s Success is Tied to Sprycel
7.2.5 Bayer Healthcare: Nexavar and Stivarga
7.2.6 AstraZeneca Needs the US Market To Succeed
7.2.7 Gilead Sciences
7.3 Other Companies
7.3.1 AbbVie
7.3.2 Boehringer Ingelheim BioXcellence

8. Qualitative Analysis of the Anti-Cancer Kinase Inhibitors Market, 2015-2025
8.1 SWOT Analysis of the Anti-Cancer Kinase Inhibitors Market
8.2 Strengths
8.2.1 Personalised Medicine is a Strong Trend in Cancer Treatment
8.2.2 Targeted Kinase Inhibitors are Generally Well-Tolerated
8.2.3 Strong Pipeline of Novel Inhibitors Will Drive Market Growth
8.2.4 Oral Dosage is the Preferred Treatment
8.3 Weaknesses
8.3.1 High-Cost of Treatment May Restrain the Market
8.3.2 Ease of Manufacturing Small Molecule Drugs
8.3.3 Monoclonal Antibodies are More Specific than Small Molecules
8.4 Opportunities
8.4.1 Ageing Populations and Rising Cancer Prevalence Will Increase Demand for Treatment
8.4.2 Investment into Research May Lead to Improved Targeted Treatments
8.4.3 Combination Therapies Bring Additive Benefits
8.5 Threats
8.5.1 Regulations: Can they Restrain the Market?
8.5.2 Multiple Companies Competing
8.6 STEP Analysis of the Anti-Cancer Kinase Inhibitors Market

9. Research Interviews
9.1 Interview with Dr Lawrence Bloch, Chief Finance and Business Officer, Infinity Pharmaceuticals, United States
9.1.1 Positioning a Novel Therapeutic in Blood Cancer Indications
9.1.2 Combining Therapies Offers Significant Benefit to Patients
9.1.3 Potential in Rheumatoid Arthritis and Blood Cancers
9.2 Interview with Dr Marcel Spaargaren, Associate Professor, LYMMCARE (Lymphoma and Myeloma Center Amsterdam)
9.2.1 Combining Two Kinase Inhibitor Therapeutics
9.2.2 Expectations for Kinase Inhibitor Therapies as Cancer Treatments
9.2.3 The Future of B-Cell Receptor Inhibitors

10. Conclusions from the Research and Analysis
10.1 World Anti-Cancer Kinase Inhibitors Market: Outlook from 2015
10.1.1 Recent Launches of Innovative Drugs and a Robust Pipeline Will Drive Market Growth
10.2 Opportunities in Developed and Developing National Pharma Markets Expanding Those Drug Sales

List of Tables
Table 1.1 Human Kinome, 2015
Table 1.2 Foreign Currency Exchange Rates to $US
Table 3.1 Glivec Indications, 2015
Table 3.2 Seven Orphan Drug Designations for Glivec, 2015
Table 3.3 Glivec Revenue Forecast ($bn), 2014-2025
Table 3.4 Sprycel Revenue Forecast ($bn), 2014-2025
Table 3.5 Tasigna Revenue Forecast ($bn), 2014-2025
Table 3.6 Bosulif Revenue Forecast ($bn), 2014-2025
Table 3.7 Iclusig Revenue Forecast ($bn), 2014-2025
Table 3.8 Tarceva Revenue Forecast ($bn), 2014-2025
Table 3.9 Iressa Revenue Forecast ($bn), 2014-2025
Table 3.10 Gilotrif Revenue Forecast ($bn), 2014-2025
Table 3.11 Nexavar Revenue Forecast ($bn), 2014-2025
Table 3.12 Sutent Revenue Forecast ($bn), 2014-2025
Table 3.13 Votrient Revenue Forecast ($bn), 2014-2025
Table 3.14 Inlyta Revenue Forecast ($bn), 2014-2025
Table 3.15 Zelboraf Revenue Forecast ($bn), 2014-2025
Table 3.16 Tafinlar Revenue Forecast ($bn), 2014-2025
Table 3.17 Mekinist Revenue Forecast ($bn), 2014-2025
Table 3.18 Afinitor Revenue Forecast ($bn), 2014-2025
Table 3.19 Torisel Revenue Forecast ($bn), 2014-2025
Table 3.20 Zydelig Revenue Forecast ($bn), 2014-2025
Table 3.21 Imbruvica Revenue Forecast ($bn), 2014-2025
Table 3.22 Jakavi Revenue Forecast ($bn), 2014-2025
Table 3.23 Xalkori Revenue Forecast ($bn), 2014-2025
Table 3.24 Cometriq Revenue Forecast ($bn), 2014-2025
Table 3.25 Caprelsa Revenue Forecast ($bn), 2014-2025
Table 3.26 Tyverb Revenue Forecast ($bn), 2014-2025
Table 3.27 Stivarga Revenue Forecast ($bn), 2014-2025
Table 3.28 Zykadia Revenue Forecast ($bn), 2014-2025
Table 3.29 Ibrance Revenue Forecast ($bn), 2014-2025
Table 3.30 Alectinib Revenue Forecast ($bn), 2014-2025
Table 4.1 Global Market for Anti-Cancer Kinase Inhibitors: Revenues ($bn) and Market Shares (%) by Class, 2014
Table 4.2 Top Five Anti-Cancer Kinase Inhibitors by Revenue ($bn), 2014
Table 4.3 Global Market Forecasts for Anti-Cancer Kinase Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2014-2019
Table 4.4 Global Market Forecasts for Anti-Cancer Kinase Inhibitors by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2020-2025
Table 4.5 Global Market Forecast for Anti-Cancer Kinase Inhibitors by Class: Market Shares (%), 2014-2025
Table 4.6 Forecast Global Market for Bcr-Abl Kinase Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 4.7 Drivers and Restraints of the Bcr-Abl Kinase Inhibitor Market, 2015-2025
Table 4.8 Forecast Global Market for Other Kinase Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2014-2025
Table 4.9 Drivers and Restraints of the Other Kinase Inhibitor Market, 2015-2025
Table 5.1 Regional Breakdown of the Anti-Cancer Kinase Inhibitor Market: Market Sizes ($bn), Market Shares (%), 2014
Table 5.2 Forecast Regional Anti-Cancer Kinase Inhibitor Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%) 2014-2019
Table 5.3 Forecast Regional Anti-Cancer Kinase Inhibitor Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%) 2019-2025
Table 5.4 Forecast Regional Anti-Cancer Kinase Inhibitor Markets: Market Shares (%), 2014-2025
Table 5.5 Forecast of US Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.6 Drivers and Restraints of the US Kinase Inhibitor Market, 2015-2025
Table 5.7 EU Market Shares (%), 2014-2025
Table 5.8 Forecasts of EU Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2019
Table 5.9 Forecasts of EU Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2020-2025
Table 5.10 Drivers and Restraints of the EU Kinase Inhibitor Market, 2015-2025
Table 5.11 Forecast of German Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.12 Forecast of French Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.13 Forecast of Italian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.14 Forecast of UK Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.15 Forecast of Spanish Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.16 Forecast for Japanese Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.17 Forecast Anti-Cancer Kinase Inhibitor Markets in the BRIC Nations: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2014-2025
Table 5.18 Forecast for Chinese Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.19 Forecast for Indian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.20 Forecast for Brazilian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 5.21 Forecast for Russian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 6.1 LEE-011 Revenue Forecast ($bn), 2016-2025
Table 6.2 Abemaciclib Revenue Forecast ($bn), 2017-2025
Table 6.3 Venetoclax Revenue Forecast ($bn), 2016-2025
Table 6.4 Duvelisib Revenue Forecast ($bn), 2017-2025
Table 6.5 Buparlisib Revenue Forecast ($bn), 2017-2025
Table 6.6 Cobimetinib Revenue Forecast ($bn), 2014-2025
Table 6.7 Volasertib Revenue Forecast ($bn), 2017-2025
Table 7.1 Leading Companies in the Anti-Cancer Kinase Inhibitor Market: Revenue ($bn), Market Share (%), 2014
Table 7.2 Top Five Anti-Cancer Kinase Inhibitors by Revenue: Company, Drug, Indication(s), Molecular Target, Global Revenue, 2014
Table 7.3 Leading Anti-Cancer Kinase Inhibitors Manufacturers: Product Revenues ($bn), 2014-2019
Table 7.4 Leading Anti-Cancer Kinase Inhibitors Manufacturers: Product Revenues ($bn), 2020-2025
Table 7.5 Novartis Anti-Cancer Kinase Inhibitor Market: Revenue ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 7.6 Pfizer Anti-Cancer Kinase Inhibitor Market: Revenue ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 7.7 Roche Anti-Cancer Kinase Inhibitor Market: Revenue ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 7.8 Bristol-Myers Squibb Anti-Cancer Kinase Inhibitor Market: Revenue ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 7.9 Bayer Anti-Cancer Kinase Inhibitor Market: Revenue ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 7.10 AstraZeneca Anti-Cancer Kinase Inhibitor Market: Revenue ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 7.11 Gilead Sciences Anti-Cancer Kinase Inhibitor Market: Revenue ($bn), Annual Growth (%), CAGR (%), 2014-2025
Table 7.12 Imbruvica Indications and FDA Approvals, 2015
Table 8.1 Social, Technological, Economic, and Political Factors (STEP) Affecting the Anti-Cancer Kinase Inhibitor Market, 2015
Table 10.1 Anti-Cancer Kinase Inhibitor Market Forecasts by Class: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019, and 2025
Table 10.2 Anti-Cancer Kinase Inhibitor Market Forecasts by Region: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019, and 2025

List of Figures
Figure 1.1 Segments of the Kinase Inhibitors Market for Cancer Treatment, 2015
Figure 3.1 Glivec Revenue Forecast ($bn), 2014-2025
Figure 3.2 Sprycel Revenue Forecast ($bn), 2014-2025
Figure 3.3 Tasigna Revenue Forecast ($bn), 2014-2025
Figure 3.4 Bosulif Revenue Forecast ($bn), 2014-2025
Figure 3.5 Iclusig Revenue Forecast ($bn), 2014-2025
Figure 3.6 Tarceva Revenue Forecast ($bn), 2014-2025
Figure 3.7 Iressa Revenue Forecast ($bn), 2014-2025
Figure 3.8 Gilotrif Revenue Forecast ($bn), 2014-2025
Figure 3.9 Nexavar Revenue Forecast ($bn), 2014-2025
Figure 3.10 Sutent Revenue Forecast ($bn), 2014-2025
Figure 3.11 Votrient Revenue Forecast ($bn), 2014-2025
Figure 3.12 Inlyta Revenue Forecast ($bn), 2014-2025
Figure 3.13 Zelboraf Revenue Forecast ($bn), 2014-2025
Figure 3.14 Tafinlar Revenue Forecast ($bn), 2014-2025
Figure 3.15 Mekinist Revenue Forecast ($bn), 2014-2025
Figure 3.16 Afinitor Revenue Forecast ($bn), 2014-2025
Figure 3.17 Torisel Revenue Forecast ($bn), 2014-2025
Figure 3.18 Zydelig Revenue Forecast ($bn), 2014-2025
Figure 3.19 Imbruvica Revenue Forecast ($bn), 2014-2025
Figure 3.20 Jakavi Revenue Forecast ($bn), 2014-2025
Figure 3.21 Xalkori Revenue Forecast ($bn), 2014-2025
Figure 3.22 Cometriq Revenue Forecast ($bn), 2014-2025
Figure 3.23 Caprelsa Revenue Forecast ($bn), 2014-2025
Figure 3.24 Tyverb Revenue Forecast ($bn), 2014-2025
Figure 3.25 Stivarga Revenue Forecast ($bn), 2014-2025
Figure 3.26 Zykadia Revenue Forecast ($bn), 2014-2025
Figure 3.27 Ibrance Revenue Forecast ($bn), 2014-2025
Figure 3.28 Alectinib Revenue Forecast ($bn), 2014-2025
Figure 4.1 Global Market for Anti-Cancer Kinase Inhibitors: Market Shares by Class (%), 2014
Figure 4.2 Top Five Anti-Cancer Kinase Inhibitors by Revenue: Market Shares (%), 2014
Figure 4.3 Global Market Forecast for Anti-Cancer Kinase Inhibitors by Class: Market Sizes ($bn), 2014-2025
Figure 4.4 Global Market for Anti-Cancer Kinase Inhibitors by Class: Market Shares (%), 2019
Figure 4.5 Global Market for Anti-Cancer Kinase Inhibitors by Class: Market Shares (%), 2025
Figure 4.6 Forecast Global Market for Bcr-Abl Kinase Inhibitors: Revenue ($bn), 2014-2025
Figure 4.7 Forecast Global Market for Other Kinase Inhibitors: Revenue ($bn), 2014-2025
Figure 5.1 Regional Breakdown of the Anti-Cancer Kinase Inhibitor Market: Market Shares (%), 2014
Figure 5.2 Forecast Regional Anti-Cancer Kinase Inhibitor Markets: Market Sizes ($bn), 2014-2025
Figure 5.3 Forecast Regional Anti-Cancer Kinase Inhibitor Markets: Market Shares (%), 2019
Figure 5.4 Forecast Regional Anti-Cancer Kinase Inhibitor Markets: Market Shares (%), 2025
Figure 5.5 US Anti-Cancer Kinase Inhibitor Market ($bn), 2014-2025
Figure 5.6 EU Market for Anti-Cancer Kinase Inhibitors by Leading Country (%), 2014
Figure 5.7 Forecast of EU Anti-Cancer Kinase Inhibitor Market, Market Sizes ($bn), 2014-2025
Figure 5.8 Forecast of German Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2014-2025
Figure 5.9 Forecast of French Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2014-2025
Figure 5.10 Forecast of Italian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2014-2025
Figure 5.11 Forecast of UK Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2014-2025
Figure 5.12 Forecast of Spanish Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2014-2025
Figure 5.13 Forecast for Japanese Anti-Cancer Kinase Inhibitor Market Size ($bn), 2014-2025
Figure 5.14 Forecast Anti-Cancer Kinase Inhibitor Markets in the BRIC Nations: Market Size ($bn), 2014-2025
Figure 5.15 Forecast for Chinese Anti-Cancer Kinase Inhibitor Market Size ($bn), 2014-2025
Figure 5.16 Forecast for Indian Anti-Cancer Kinase Inhibitor Market Size ($bn), 2014-2025
Figure 5.17 Forecast for Brazilian Anti-Cancer Kinase Inhibitor Market Size ($bn), 2014-2025
Figure 5.18 Forecast for Russian Anti-Cancer Kinase Inhibitor Market Size ($bn), 2014-2025
Figure 6.1 LEE-011 Revenue Forecast ($bn), 2016-2025
Figure 6.2 Abemaciclib Revenue Forecast ($bn), 2017-2025
Figure 6.3 Venetoclax Revenue Forecast ($bn), 2016-2025
Figure 6.4 Duvelisib Revenue Forecast ($bn), 2017-2025
Figure 6.5 Buparlisib Revenue Forecast ($bn), 2017-2025
Figure 6.6 Cobimetinib Revenue Forecast ($bn), 2014-2025
Figure 6.7 Volasertib Revenue Forecast ($bn), 2017-2025
Figure 7.1 Leading Companies in the Protein Kinase Inhibitor Market: Market Shares (%), 2014
Figure 7.2 Top Five Anti-Cancer Kinase Inhibitors by Revenue: Market Shares, 2014
Figure 7.3 Leading Anti-Cancer Kinase Inhibitors Manufacturers: Product Revenues ($bn), 2014-2025
Figure 7.4 Novartis Anti-Cancer Kinase Inhibitor Market ($bn), 2014-2025
Figure 7.5 Pfizer Anti-Cancer Kinase Inhibitor Market ($bn), 2014-2025
Figure 7.6 Roche Anti-Cancer Kinase Inhibitor Market ($bn), 2014-2025
Figure 7.7 Bristol-Myers Squibb Anti-Cancer Kinase Inhibitor Market ($bn), 2014-2025
Figure 7.8 Bayer Anti-Cancer Kinase Inhibitor Market ($bn), 2014-2025
Figure 7.9 AstraZeneca Anti-Cancer Kinase Inhibitor Market ($bn), 2014-2025
Figure 7.10 Gilead Sciences Anti-Cancer Kinase Inhibitor Market ($bn), 2014-2025
Figure 10.1 Anti-Cancer Kinase Inhibitor Market Forecast by Class: Market Sizes ($bn), 2014, 2019, and 2025
Figure 10.2 Anti-Cancer Kinase Inhibitor Market Forecasts by Region: Market Size ($bn), 2014, 2019, and 2025

【レポートのキーワード】

キナーゼ阻害剤、がん治療、医薬品、新生阻害剤、EGFR阻害剤、mTOR阻害剤、BRAF阻害剤、MEK阻害剤、キナーゼ阻害薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ がん治療用キナーゼ阻害剤の世界市場(Kinase Inhibitors for Cancer Treatment: World Industry Analysis, R&D and Market Forecasts 2015-2025
: Explore the Potentials of New Drugs)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆